Brief: ABVC Biopharma & Biolite Entered Into Definitive Agreement With Oncox Biopharma To Collaborate On Combination Therapy
24/05/2024 13:31
May 24 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA- CO & BIOLITE ENTERED INTO DEFINITIVE
AGREEMENT
WITH ONCOX BIOPHARMA TO COLLABORATE ON COMBINATION THERAPY
* ABVC BIOPHARMA- ABVC & UNIT ARE ELIGIBLE TO RECEIVE
AGGREGATE
LICENSE FEE OF $12.5 MILLION IN FORM OF CASH OR SHARES OF ONCOX
SECURITIES
* ABVC BIOPHARMA- UNDER TERMS OF DEAL, ABVC GRANTS ONCOX
EXCLUSIVE
RIGHTS FOR ONE OF ABVC’S FOUR PRODUCTS IN ITS ONCOLOGY PIPELINE
Source text for Eikon: ID:n0001213900-24-046419
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner